Machina Capital S.A.S. Invests $206,000 in Exelixis, Inc. (NASDAQ:EXEL)

Machina Capital S.A.S. bought a new position in Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,187 shares of the biotechnology company’s stock, valued at approximately $206,000.

A number of other institutional investors have also recently modified their holdings of the stock. Principal Securities Inc. boosted its position in shares of Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares during the last quarter. USA Financial Formulas purchased a new stake in shares of Exelixis during the fourth quarter valued at $32,000. Kestra Investment Management LLC purchased a new stake in shares of Exelixis during the fourth quarter valued at $39,000. UMB Bank n.a. boosted its position in shares of Exelixis by 68.4% during the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 553 shares during the last quarter. Finally, V Square Quantitative Management LLC boosted its position in shares of Exelixis by 37.3% during the fourth quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 425 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Stock Up 1.0 %

NASDAQ EXEL opened at $38.58 on Monday. The stock’s 50-day moving average price is $34.99 and its 200-day moving average price is $32.12. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $39.30. The company has a market capitalization of $10.80 billion, a P/E ratio of 21.80, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Activity at Exelixis

In related news, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the sale, the director now owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. This trade represents a 28.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the sale, the executive vice president now directly owns 303,310 shares in the company, valued at $11,216,403.80. This trade represents a 14.79 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Truist Financial increased their price objective on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Piper Sandler increased their price objective on Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $30.00 to $40.00 in a research report on Monday, January 27th. Stephens reissued an “equal weight” rating and issued a $29.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Finally, Oppenheimer cut Exelixis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $41.00 to $33.00 in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.24.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.